Phosphodiesterase 5 inhibitors: Current status and potential applications

Nature Reviews Drug Discovery

Volumn 1, Issue 9, 2002, Pages 674-682

  Rotella, David P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; ESTERASE INHIBITOR; FR 226807; ILOPROST; KF 31327; MILRINONE; MIRTAZAPINE; ORGANIC NITRATE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIDAZINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TA 1790; TADALAFIL; UDENAFIL; UK 369003; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; ZAPRINAST; CARBOLINE DERIVATIVE; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SULFONE; TRIAZINE DERIVATIVE;

CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; DYSPEPSIA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HEADACHE; HEART INFARCTION; HOT FLUSH; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; RHINITIS; STROKE; STRUCTURE ACTIVITY RELATION; CHEMISTRY; GENETICS; IMPOTENCE; PHYSIOLOGY;

CARBOLINES; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; TRIAZINES;

EID: 0036717930     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd893     Document Type: Review

References (55)

1. Corbin, J. D. & Francis, S. H. Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 274, 13729-13732 (1999).
2. Fawcett, L. et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11a. Proc. Natl Acad. Sci. USA 97, 3702-3707 (2000).
3. Francis, S. H., Lincoln, T. M. & Corbin, J. D. Characterization of a novel cGMP binding protein from rat lung. J. Biol. Chem. 255, 620-626 (1980).
4. McAllister-Lucas, L. M. et al. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J. Biol. Chem. 268, 22863-22873 (1993).
5. Corbin, J. D., Turko, I. V., Beasley, A. & Francis, S. H. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide dependent protein kinase alters its catalytic and allosteric cGMP binding activities. Eur. J. Biochem. 267, 2760-2767 (2000).
6. Lin, C.-S., Lau, A., Tu, R. & Lue, T. F. Expression of three isoforms of cGMP-binding, cGMP- specific phosphodiesterase (PDE5) in human penile tissue. Biochem. Biophys. Res. Commun. 268, 628-635 (2000).
7. Yanaka, N. et al. Expression, structure and chromosomal localization of the human cGMP-binding, cGMP-specific phosphodiesterase PDE5A gene. Eur. J. Biochem. 255, 391-399 (1998).
8. Loughney, K. et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP binding, cGMP specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216, 139-147 (1998).
9. Turko, I. V., Ballard, S. A., Francis, S. H. & Corbin, J. D. Inhibition of cyclic GMP binding, cyclic GMP specific phosphodiesterase 5 by sildenafil and related compounds. Mol. Pharmacol. 56, 124-130 (1999).
10. Turko, I. V., Francis, S. H. & Corbin, J. D. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding and cGMP-specific phosphodiesterase 5. CGMP versus cAMP substrate selectivity. Biochemistry 37, 4200-4205 (1998).
11. Lue, T. F. Erectile dysfunction. N. Engl. J. Med. 324, 1802-1813 (2000).
12. Rotella, D. P. Phosphodiesterase type 5 inhibitors: discovery and therapeutic utility. Drugs Future 26, 153-162 (2001).
13. Kloner, R. A., Brown, M., Prisant, L. M. & Collins, M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am. J. Hypertens. 14, 70-73 (2001).
14. Conti, R. C., Pepine, C. J. & Sweeney, M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am. J. Cardiol. 83, 29C-34C (1999).
15. Price, D. E. et al. Sildenafil: a study of a novel oral treatment for erectile dysfunction in diabetic men. Diabetic Med. 15, 821-825 (1998).
16. Derry, F. A. et al. Efficacy and safety of oral sildenafil (Viagra™) in men with erectile dysfunction caused by spinal cord injury. Neurology 51, 1629-1633 (1998).
17. Fava, M., Rankin, M. A., Alpert, J. F., Nierenberg, A. A. & Worthington, J. J. An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. Psychother. Pyschosom. 67, 328-331 (1998).
18. Hanning, H. et al. Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones: a new class of potent PDE5 inhibitors. Bioorg. Med. Chem. Lett. 12, 865-868 (2002).
19. Terret, N. K., Bell, A. S., Brown, D. & Ellis, P. Sildenafil (Viagra™) a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 6, 1819-1824 (1996).
20. Klotz, T. et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J. Urol. 19, 32-39 (2001).
21. Porst, H. et al. The efficacy and tolerability of vardenafil, a new oral selective phosphodiesterase type 5 inhibitor in patients with erectile dysfunction: the first at home clinical trial. Int. J. Impotence Res. 13, 192-199 (2001).
22. Vardenafil effective and safe as ED therapy in men with prostatectomy, CAD and hypertension. Prous Daily Essentials (February 27, 2002).
23. US delay for Lilly Icos's Cialis. Scrip World Pharmaceutical News (May 1, 2002).
24. Porst, H. IC351 (tadalafil, Cialis™): update on clinical experience. Int. J. Impotence Res. 14 (Suppl. 1), S57-S64 (2002).
25. Porst, H. et al. Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose. J. Urol. 167 (Suppl.), 177 (2002).
26. Padma-Nathan, H., Rosen, R. C., Shobsigh, R., Watkins, V. S. & Pullman, B. Cialis (IC351) provides prompt response and extended responsiveness for the treatment of erectile dysfunction. J. Urol. 165 (Suppl.), 224 (2001).
27. Hutter, A. M. et al. Blood pressure and cardiovascular effects of tadalafil, a new PDE5 inhibitor. Am. J. Hypertens. 15 (Part 2), 140A (2002).
28. Padma-Nathan, H. et al. Efficacy and safety of tadalafil in men with erectile dysfunction with and without hypertension. Am. J. Hypertens. 15 (Part 2), 143A (2002).
29. Vivus cleared to proceed with TA-1790 trial in erectile dysfunction. Prous Daily Essentials (January 22, 2002).
30. Oh, T. Y., Kang, K. K., Ahn, B. O., Yoo, M. & Kim, W. B. Erectogenic effect of the selective phosphodiesterase inhibitor DA-8159. Arch. Pharm. Res. 23, 471-476 (2000).
31. Hosogai, N. et al. FR226807: a potent and selective phosphodiesterase type 5 inhibitor. Eur. J. Pharmcol. 428, 295-302 (2001).
32. Kotera, J. et al. Characterization and effects of methyl-2-(4- aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridylmethoxy)-4- (3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032) a novel potent inhibitor of cGMP-binding, cBMP-specific phosphodiesterase (PDE5). Biochem. Pharmacol. 60, 1333-1341 (2000).
33. Takagi, M. et al. Pharmacologic profile of T-1032, a novel, specific phosphodiesterase type 5 inhibitor in isolated rat aorta and rabbit corpus cavernosum. Eur. J. Pharmacol 411, 161-168 (2001).
34. Inoue, H., Yano, K., Ikeo, T., Noto, T. & Kikkawa, K. T-1032 a novel specific phosphodiesterase type 5 inhibitor increases venous compliance in anesthetized rats. Eur. J. Pharmacol. 422, 109-114 (2001).
35. Ukita, T. et al. Novel potent and selective PDE5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives. J. Med. Chem. 44, 2204-2218 (2001).
36. Hirose, R. et al. KF31327 a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. Eur. J. Pharmacol. 431, 17-24 (2001).
37. Kim, D.-K. et al. Synthesis and phosphodiesterase 5 inhibitory activity of novel phenyl ring modified sildenafil analogs. Bioorg. Med. Chem. 9, 1609-1616 (2001).
38. Kim, D.-K. et al. Synthesis and phosphodiesterase 5 inhibitory activity of new 5-phenyl-1,6-dihydro-7H-pyrazolo-[4,3d]pyrimidin-7-one derivatives containing an N-acylamido group on a phenyl ring. Bioorg. Med. Chem. 9, 1895-1899 (2001).
39. Rotella, D. P. et al. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for the treatment of erectile dysfunction. J. Med. Chem. 43, 1257-1263 (2001).
40. Kim, D.-K. et al. Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogs containing a carboxylic acid group in the 5′-sulfonamide moiety of a phenyl ring. Bioorg. Med. Chem. 9, 3013-3021 (2001).
41. Bi, Y. et al. The discovery of novel potent and selective PDE5 inhibitors. Bioorg. Med. Chem Lett. 11, 2461-2464 (2001).
42. Yu, G. et al. Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. J. Med. Chem. 44, 1025-1027 (2001).
43. Kumar, V. & Dority, J. A. Jr. Preparation of N-cycloalkylmethyl-1H-pyrazolo[3,4b]quinoline-4-amines as cGMP phosphodiesterase inhibitors. US patent 5,488,055 (1996).
44. Vemulapalli, S. & Kuroski, S. Sildenafil relaxes rabbit clitoral corpus cavernosum. Life Sci. 67, 23-29 (2000).
45. Min, K. et al. Sildenafil augments pelvic nerve mediated female genital sexual arousal in the anesthetized rabbit. Int. J. Impotence Res. 12 (Suppl. 3), S32-S39 (2000).
46. Reis, R. B. et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 53, 481-486 (1999).
47. Caruso, S., Intelisano, G., Lupo, L. & Agnello, C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study Br. J. Obstet. Gynaecol. 108, 623-628 (2001).
48. McPherson, M. A., Pereira, M. M. C., Mills, C. L., Murray, K. J. & Dormer, R. L. A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein. FEBS Lett. 464, 48-52 (1999).
49. Bortolotti, M., Mari, C., Lopilato, C., Porrazzo, G. & Miglioli, M. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology 118, 253-257 (2000).
50. Bortolotti, M., Mari, C., Lopilato, C., La Rovere, L. & Miglioli, M. Sildenafil inhibits gastroduodenal motility. Aliment. Pharmacol. Ther. 15, 157-161 (2001).
51. Wilkens, H. et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104, 1218-1222 (2001).
52. Sobey, C. G. Cerebrovascular dysfunction after subarachnoid hemorrhage: novel mechanisms and directions for therapy. Clin. Exp. Pharmacol. Physiol. 28, 926-929 (2001).
53. Sildenafil demonstrates beneficial activity in rat model of cerebral ischemia. Prous Daily Essentials (February 7, 2002).
54. Berkels, R., Klotz, T., Sticht, G., Englemann, U. & Klaus, W. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J. Cardiovasc. Pharmacol. 37, 413-421 (2001).
55. Soderling, S. H. & Beavo, J. A. Regulation of cAMP and cGMP signalling: new phosphodiesterases and new functions. Curr. Opin. Cell. Biol. 12, 174-179 (2000).